Trastuzumab For HER2-Positive BC may be linked to CNS Mets

Options

Trastuzumab For HER2-Positive Breast Cancer May Be Linked To CNS Metastases.

Medscape (3/15, Lowry) reports, "Women with HER2-positive breast cancer who receive adjuvant trastuzumab (Herceptin, Genentech/Roche) have a significant risk for metastases in the central nervous system (CNS) as the site of first recurrence, according to a report published online March 4 in the Annals of Oncology." Investigators looked at data from four trials. They found that, "of the 4921 patients who received adjuvant trastuzumab, 125 developed CNS metastases as the site of first recurrence, for an overall incidence of 2.56% (95% confidence interval [CI], 2.07% - 3.01%)." In comparison, "of the 4099 patients who did not receive trastuzumab, there were 78 CNS events, for an incidence of 1.94% (95% CI, 1.54% - 2.38%)."

Comments

Categories